Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on May 23, 2022. The filing serves to announce the company's financial results for the three-month period ended March 31, 2022. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reported period. These figures are referenced as being available in the attached press release (Exhibit 99.1).
Material Changes
No material changes versus the prior comparable period are detailed in this specific document text. The filing solely references the issuance of the Q1 2022 results without summarizing the variances.
Guidance, Outlook, and Risks
The document does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information furnished pursuant to Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the correct registrant name is ReShape Lifesciences Inc. (RSLS), not Vyome Holdings, Inc.
- Review Exhibit 99.1 (Press Release dated May 23, 2022) to obtain actual revenue, net loss, and cash position figures.
- Confirm the reporting period is the quarter ended March 31, 2022.
- Note that the financial data in this 8-K is "furnished" and not "filed" under Section 18 of the Exchange Act.